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Abstract
Background: Recruitment to randomised prevention trials is challenging, not least for intracerebral haemorrhage
(ICH) associated with antithrombotic drug use. We investigated reasons for not recruiting apparently eligible
patients at hospital sites that keep screening logs in the ongoing REstart or STop Antithrombotics Randomised Trial
(RESTART), which seeks to determine whether to start antiplatelet drugs after ICH.
Method: By the end of May 2015, 158 participants had been recruited at 108 active sites in RESTART. The trial
coordinating centre invited all sites that kept screening logs to submit screening log data, followed by one
reminder. We checked the integrity of data, focused on the completeness of data about potentially eligible patients
and categorised the reasons they were not randomised.
Results: Of 108 active sites, 39 (36%) provided usable screening log data over a median of ten (interquartile
range = 5–13) months of recruitment per site. During this time, sites screened 633 potentially eligible patients
and randomised 53 (8%) of them. The main reasons why 580 patients were not randomised were: 43 (7%)
patients started anticoagulation, 51 (9%) patients declined, 148 (26%) patients’ stroke physicians were not
uncertain about using antiplatelet drugs, 162 (28%) patients were too unwell and 176 (30%) patients were
not randomised due to other reasons.
Conclusion: RESTART recruited ~8% of eligible patients. If more physicians were uncertain about the
therapeutic dilemma that RESTART is addressing, RESTART could have recruited up to four times as many
participants. The trial coordinating centre continues to engage with physicians about their uncertainty.
Trial registration: EU Clinical Trials, EudraCT 2012-003190-26. Registered on 3 July 2012.
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Background
Research into methods to boost recruitment has been
identified as the highest priority for randomised con-
trolled trials (RCTs) methodological research in the UK
[1]. The Lancet’s series on ‘Research: Increasing Value
and Reducing Waste’ identified under-recruitment to
RCTs as a major source of inefficiency in the conduct of
applied clinical research [2]. Slow recruitment is particu-
larly inefficient because it delays the delivery of research
and inflates its costs by increasing the number of staff
and sites or by extending the amount and duration of
funding required.
This problem has not been small – a review of 114
RCTs funded by MRC or HTA in the UK in 1994–2002
found that less than one-third recruited their original
target within the time originally specified and around
one-third were given extensions to achieve their target
[3]. A re-investigation of this in 2002–2008 found that
almost half of the RCTs did not recruit their originally
specified target sample size and nearly half of the RCTs
received an extension of some kind [4], which was only
a marginal improvement. Recruitment is jeopardised by
many factors including restrictive eligibility criteria and
inefficient methods for approaching potential partici-
pants [5, 6]. Screening logs may help inform the repre-
sentativeness of a RCT [7], but they may also be
informative for understanding why eligible patients are
not recruited [8, 9].
Stroke due to intracerebral haemorrhage (ICH) affects
~10,000 adults in the UK each year. Within one month of
ICH ~40% of patients die and more than half the survivors
are dependent [10]. Achieving large sample sizes in ICH
RCTs is therefore challenging, especially when protocols
specify short time windows for recruitment after ICH on-
set and include many eligibility criteria [5]. Many ICH
RCTs have studied acute and rehabilitation interventions,
but only one published RCT has investigated an interven-
tion for secondary prevention; PROGRESS recruited 611
patients with ICH at 172 hospital sites in ten countries
over 30 months in 1995–1997 [11, 12].
The REstart or STop Antithrombotics Randomised
Trial (RESTART, ISRCTN71907627 www.restarttrial.org)
is an ongoing RCT comparing policies of restarting ver-
sus avoiding antiplatelet drugs for secondary prevention
after ICH. RESTART aimed to recruit 720 participants
over two years (from May 2013 to May 2015) based on
recent epidemiological data [5, 13]. RESTART has imple-
mented as many as possible of the strategies that have
been shown to maximise recruitment [5, 14, 15] includ-
ing: minimising the number of eligibility criteria, maxi-
mising the time window for recruiting patients after ICH
onset, and having an open design where participants
know which treatment they are receiving. In addition,
the Chief Investigator has used qualitative methods with
Principal Investigators at all active sites to identify and
overcome barriers to clinician recruitment activity, as
recommended by a systematic review [16].
Based on pilot data in an international collaboration
[17], 20% of all ICH patients (2% of all strokes) should
be potentially eligible for RESTART (although these data
were unable to take account of patients’ functional status
and a recent hospital-based study found that only 15%
of patients form the Lund Stroke Registry were poten-
tially eligible for RESTART [18]). We completed a quan-
titative investigation of recruitment estimates given by
sites when being activated to RESTART in February
2015, and at the time of this investigation 101 sites
expected to have recruited 741 patients, but they had in
fact recruited 135 (18%). By the end of May 2015, 108
hospital sites were active and 158 participants had been
randomised in RESTART (22% of the recruitment target
of 720 participants).
Therefore, we sought to identify the main reasons for
fewer participants being recruited than expected.
Methods
To investigate why potentially eligible patients were not
being randomised in RESTART we requested sites pro-
vide us anonymised screening logs. Although sites had
not been asked to specifically keep screening logs for the
trial, the trial coordinating centre were aware that some
centres kept them for their stroke patients as that was
their practice or they were required to by their R&D
department. By gathering these valuable data, we could
analyse what the leading reasons for not recruiting
potentially eligible patients were.
The RESTART trial coordinating centre invited all
sites by email on 7 May 2015, asking them if they could
provide anonymised logs (if they kept them) containing
a list of their patients with ICH who had been screened
at their hospital site since becoming active in RESTART
along with the outcome e.g. ‘randomised’, ‘not eligible’,
‘patient declined’, ‘doctor not uncertain’, etc. We sent a
reminder email on 22 May 2015 to maximise responses
by the deadline of 31 May 2015.
The RESTART eligibility criteria are as follows. Inclu-
sion criteria: patient age ≥ 18 years; spontaneous primary
or secondary ICH; patient had taken antithrombotic
drug(s) for the prevention of vaso-occlusive disease before
ICH onset; randomisation more than 24 h after ICH on-
set; patient and their doctor are uncertain about whether
to start or avoid antiplatelet drugs; patient is registered
with a general practitioner; brain imaging that first diag-
nosed the ICH is available; participant or representative
consent. Exclusion criteria: ICH due to preceding trauma
or haemorrhagic transformation of ischaemic stroke; pa-
tient is taking an anticoagulant drug following ICH; pa-
tient is pregnant, breastfeeding or of childbearing age and
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not taking contraception; patient and carer unable to
understand spoken or written English.
We asked RESTART hospital sites with available
screening log data to record: the date the patient was
screened; whether the patient’s diagnosis of ICH was
within the two months before screening; whether the
patient was screened as an inpatient or outpatient; and
the outcome of the screening (ineligible, eligible and ran-
domised, or eligible but not randomised). We categorised
reasons for non-recruitment of potentially eligible patients
(according to the eligibility criteria above) as follows, and
assumed that investigators had recorded the leading
reason if there had been more than one:
 Patient declined
 Doctor not uncertain
 Started anticoagulant
 Unwell / end of life / died
 Other
We reviewed the data integrity, completeness and
consistency of each submission of screening log data.
We collated data in an Excel spreadsheet and recorded
key information from each site’s submission, including:
the time period of screening log data collection, the
number of patients screened, the number of patients
that were randomised to RESTART, whether patients
were ineligible and, if eligible, the reasons why they were
not recruited (categorised as above).
Results
Of the 108 active RESTART sites emailed to invite them
to provide their screening logs, 44 (41%) provided data,
but we were unable to use data provided by five sites,
leaving data from 39 (36%) of RESTART hospital sites.
The 39 sites that returned screening logs recruited 58
patients between May 2013 and May 2015 (1.49 patients
per site) and the 69 sites that did not provide screening
logs recruited 100 patients during the same (1.45
patients per site), providing no evidence of bias among
the sites included in our analyses of screening logs.
The data from the 39 sites with screening logs covered
a median of ten (interquartile range = 5–13) months per
site. During this time, sites randomised 53 participants
and also screened 580 patients who appeared eligible but
were not randomised (ratio 1:11) (Fig. 1).
The main reasons why the 580 patients were not ran-
domised were: 43 (7%) patients started anticoagulation;
51 (9%) patients declined; 148 (26%) had stroke physi-
cians who were not uncertain about using antiplatelet
drugs; 162 (28%) patients were too unwell; and 176
(30%) patients were not randomised due to other rea-
sons, for example, lived out of catchment area, trans-
ferred to a different hospital, lost to follow-up, enrolled
in another drug trial, still under review, consented but
not recruited or no clear reason was provided (Fig. 2).
Discussion
Screening log data demonstrate that 8% of potentially
eligible patients were recruited and randomised to the
RESTART trial of secondary prevention after stroke due
to ICH. The two leading single reasons for eligible pa-
tients not being recruited was that they were too unwell/
Fig. 1 Flowchart of the identification and analysis of pertinent
screening log information
Fig. 2 Graph showing reasons for 580 potentially eligible patients
not being randomised
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disabled and that physicians were not uncertain despite
the clear shortage of evidence to inform this therapeutic
dilemma in the available literature [19, 20].
This study has some strengths. The RESTART trial re-
flects contemporary clinical practice and trial recruit-
ment at a large number of hospitals in the UK.
RESTART is the only ongoing RCT of secondary pre-
vention after ICH in the UK. We gave all sites the
opportunity to participate, checked the data that we
received and used a standardised approach to categoris-
ing reasons for non-recruitment.
This study has some weaknesses. RESTART did not
mandate sites to keep screening logs – so they were only
available at a minority of sites – but used those that were
available because sites recorded screening activity to
monitor their research activity. Sites returned data in a
variety of formats and collected data over slightly differing
time periods because there was variation in the time at
which they became active in the collaboration. We had to
omit some data due to their quality or completeness.
Screening logs appear useful for identifying the leading
reasons why eligible patients are not recruited to a RCT.
These data can inform future RCTs of pharmacological
secondary prevention RCTs after ICH, in which ~8% of
eligible participants may be recruited, although we cannot
exclude the possibility that this proportion is intervention-
specific. Physician certainty, despite the lack of rigorous
evidence to inform therapeutic decisions, remains one of
the major, potentially modifiable barriers to recruiting lar-
ger proportions of eligible patients.
Due to under-recruitment, RESTART’s funder kindly
granted an extension of recruitment until 31 May 2018.
Conclusion
Screening log data can be useful for identifying reasons for
low recruitment of eligible patients to a RCT. Approxi-
mately 8% of eligible patients were recruited to the RE-
START trial. During the period of this screening log
analysis, if some physicians had not been certain about
whether to start antiplatelet drugs after ICH for 148 poten-
tially eligible patients, RESTARTcould have almost quadru-
pled the number of participants recruited from 53 to 201.
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